Lamivudin var ikke genotoksisk in vivo ved doser, der medførte plasmakoncentrationer omkring 60- 70 gange højere end de forventede kliniske plasmakoncentrationer.
Lamivudine was not genotoxic in vivo at doses that gave plasma concentrations around 60-70 times higher than the anticipated clinical plasma levels.